ClinicalTrials.gg
CompletedNCT01768455Updated Apr 23, 2013

Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects

A Phase 1 interventional study of Gemigliptin and Glimepiride and Glimepiride in Healthy, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-04-23.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The objective of the study was to investigate the pharmacokinetic drug interaction between gemigliptin and glimepiride in healthy male subjects after oral administration concomitantly and each alone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.

First submitted before LG Life Sciences became part of LG Chem.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 to 45, healthy male subjects (at screening)
  • between 18 - 27 (at screening)
  • FPG 70-125mg/dL glucose level (at screening)
  • Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the

Exclusion criteria

Exclusion Criteria:

  • Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
  • Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)
  • Subject who had drug reaction.(gemigliptin, glimepiride, aspirin, antibiotics)
  • Subject who already participated in other trials in 90 days
  • Subject who had whole blood donation in 60 days, or component blood donation in 30 days or transfusion in 30 days currently
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Gemigliptin and Glimepiride

    Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride

    Drug: Gemigliptin and Glimepiride

  • Experimental
    Glimepiride

    Single administration of glimepiride

    Drug: Glimepiride

Interventions

  • DrugGemigliptin and Glimepiride

    Drug pages: Gemigliptin · Glimepiride

    Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7

  • Glimepiride 4mg (qd) on Day1

06

What researchers measure

Primary outcomes

  1. AUC

    To evaluate AUCτ,ss of gemigliptin and AUClast of glimepiride

    Time frame: up to 24h post-dose

  2. Cmax

    To evaluate Cmax,ss of gemigliptin and Cmax of glimepiride

    Time frame: up to 24h post-dose

Secondary outcomes

  1. Tmax

    To evaluate Tmax,ss of gemigliptin/LC15-0636 and Tmax of glimepiride/M1

    Time frame: up to 24h post-dose

  2. t1/2β

    To evaluate t1/2β of gemigliptin/LC15-0636/glimepiride/M1

    Time frame: up to 24h post-dose

  3. AUC

    To evaluate AUCτ,ss of LC15-0636 and AUClast of M1

    Time frame: up to 24h post-dose

  4. Cmax

    To evaluate Cmax,ss of LC15-0636 and Cmax of M1

    Time frame: up to 24h post-dose

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013 and a primary completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2013
First posted
Jan 15, 2013
Start
Feb 2013
Primary completionActual
Apr 2013
Last update
Apr 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01768455
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Jan 15, 2013
Start date
Feb 2013
Primary completion
Apr 2013
Last update
Apr 23, 2013

Study contacts

Kyun-Seop Bae, M.D., Ph.D.
principal investigator · Asan Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemigliptin · Glimepiride

Start the discussion